Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA User Fee Reauthorization Charges Along With Senate Passage

This article was originally published in The Gray Sheet

Executive Summary

FDA user fee and reform bill sails through Senate on 96-1 vote. House plans to take up its similar legislation this week.

You may also be interested in...

Congress Enters Final Stages On FDA Reform Bill

Legislative leaders say they remain on track to send FDA user fee reauthorization and reform legislation for the president’s signature by the end of June following House passage of bill.

Senate FDA Bill: Device Provisions

The Senate-approved Food and Drug Administration Safety and Innovation Act includes dozens of sections related to devices.

Latest Senate FDA Reform Bill Would Delay Guidance On Mobile Health Apps

The Senate user fee reauthorization and FDA reform bill, formally introduced May 15, includes several new provisions, including a moratorium on FDA issuing final guidance on mobile medical apps. The bill should see action on the Senate floor this week.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts